StockData

Immunocore vs Iovance Biotherapeutics

IMCR and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCR and IOVA compare

Iovance Biotherapeutics is the larger company, worth 2.3 times as much as Immunocore ($3.5B against $1.5B).

Iovance Biotherapeutics grew revenue faster over the last twelve months (51.3% versus 13.1% for Immunocore).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −58.2% at Iovance Biotherapeutics.

Iovance Biotherapeutics scores higher on the StockData Score (9 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCRIOVA
Size and price
Market cap$1.5B$3.5B
Share price$29.94$7.76
Change, 1 year−15.2%206%
Change, 5 years−21.4%−58.8%
Beta (5Y)0.691.29
Employees524975
StockData Score
Total score79 (better)
Valuation score1 (better)0
Growth score22
Performance score3 (better)1
Health score16 (better)
Dividend score00
Valuation
P/S3.6× (better)9.3×
P/B3.7× (better)4.3×
FCF yield−1.2% (better)−6.1%
Fair value$31.07$4.47
Margin of safety3.6% (better)−73.6%
Growth
Revenue growth (TTM)13.1%51.3% (better)
Profitability
Gross margin98.9% (better)53.2%
Operating margin−6.8% (better)−60.8%
Net margin−7.5% (better)−58.2%
FCF margin−4.2% (better)−57.0%
Return on equity−7.9% (better)−29.1%
Return on invested capital–−43.4%
Financial health
Debt / equity–0.00
Interest coverage−2.4×–
Current ratio4.625.20 (better)
Altman Z-score1.457.83 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield–−8.3%
Shareholder yield0.00% (better)−8.3%
Ownership
Held by institutions102%63.3%
Held by insiders15.5%0.38%
Insider net buying, 12 months−$1.9M–
Short interest, % of float–14.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.